Liftstream is an executive search recruitment company in the life sciences sector
Fidelity Biosciences and REGENX launch new gene therapy company
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged AAV, Allan M. Fox, Ben Auspitz, deno-associated virus, Dimension Therapeutics, Donald J. Hayden, Emil Kakkis, Fidelity Biosciences, FOXKISER, Gene therapy, genetic disease, Genzyme, hemophilia, investors, James Wilson, REGENX, Sam Wandsworth, series A funding, Thomas R. Beck, Ultragenyx, venture capital
Leave a comment
10 companies driving forward the rare disease market
Authored by Liftstream
Posted in Orphan Drugs and Rare Diseases
Tagged Aegerion, Amicus Therapeutics, Duchenne Muscular Dystrophy, Liftstream Rare Disease Day, Oxyrane, Promethera, Prosensa, PTC Therapeutics, Rare Disease, Rare Disease Day 2013, Sangart, Sarepta Therapeutics, Synageva, Ultragenyx, White Paper, world orphan drug congress
Leave a comment
Ultragenyx focused on ultra-rare disease future
Authored by Paul Foster
Posted in Orphan Drugs and Rare Diseases
Tagged 2013, Baylor Research Institute, BioMarin, biotech, Emil Kakkis, Fatty Acid Oxidisation Disorders, funding, Genzyme, Heriditary Inclusion Body Myopathy, IPO, Liftstream, Rare Disease, rare disease day, Sanofi, Series B, Shire, Sialic Acid, Sly Syndrome, Sudden Infant Death Syndrome, triheptanoin, ultra-rare, Ultragenyx
Leave a comment
13 Life Science Leaders to watch in 2013
Authored by Liftstream
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Abbott, AbbVie, Amgen, Angus Russell, AstraZeneca, Bluebird bio, Cancer Vaccine, CEO, Cystic Fibrosis, Dalvir Gill, David Mott, Director General EFPIA, EFPIA, EMEA, Erbitux, FDA, Flemming Ornskov, Foundation Medicine, FoundationOne, Gattex, Gene therapy, Gilead Sciences, Glybera, HCV, Hepatitis, Humira, INSPIRE, Jeff Leiden, Jeremy Levin, John Martin, Kalydeco, Karl-Ludwig Kley, Lotus Tissue Repair, Merck KGaA, Michael Pellini, Natpara, New Enterprise Associates, NP Pharmaceuticals, oncology, Orphan drugs, Pascal Soriot, rare diseases, Richard Bergstrom, Richard Gonzalez, Shire, Shire Speciality pharma, Sofosbuvir, Stimuvax, Takeda, Teva, TransCelerate, Ultragenyx, uniQure, Vertex Pharmaceuticals, Vyvanse
Leave a comment
Rare Disease Year in Review
This year has been a tumultuous year for the rare diseases market with a number of significant news stories revolving around M&A rumours, regulatory approvals, IPO’s, investments and partnering agreements. Liftstream takes a look at these events:
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business, Recruitment Market
Tagged Actelion, Alexion, BioMarin, BlubirdBio, Chiesi, Elelyso, Emil Kakkis, Enobia, Forbes, Genzyme, IPO, Lysogene, M&A, Prosensa, Protalix, rare diseases, regulatory affairs, regulatory approval, Replagal, Sanofi, Shire, Soliris, Supernus Pharmaceuticals, ultra-rare diseases, Ultragenyx, uniQure, VPRIV
Leave a comment